Comparative Effectiveness of Upadacitinib vs. Other JAK Inhibitors in Patients With Rheumatoid Arthritis in a Global Real-World Setting

Key Points

• This research aims to analyze the effectiveness of upadacitinib compared to other JAK inhibitors in achieving remission in rheumatoid arthritis patients.
• Conducted as a real-world study
• Compared outcomes among patients using upadacitinib and those using other JAK inhibitors
• Assessed physician-reported DAS28 remission and medication adherence
• Patients receiving upadacitinib achieved higher DAS28 remission rates
• Greater absence of pain reported in patients on upadacitinib
• Patients on upadacitinib showed complete adherence to medication more than those on other JAK inhibitors